tiprankstipranks
Guardant Health (GH)
NASDAQ:GH
US Market
GH
Guardant Health
RESEARCH TOOLSreports
Want to see GH full AI Analyst Report?

Guardant Health (GH) Stock Forecast & Price Target

2,224 Followers
See the Price Targets and Ratings of:

GH Analyst Ratings

Strong Buy
17Ratings
Strong Buy
17 Buy
0 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Guardant
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GH Stock 12 Month Forecast

Average Price Target

$136.94
▲(51.55% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $136.94 with a high forecast of $160.00 and a low forecast of $120.00. The average price target represents a 51.55% change from the last price of $90.36.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"$40","161":"$161","70.25":"$70.3","100.5":"$100.5","130.75":"$130.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":160,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$160.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":136.9375,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$136.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$120.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,70.25,100.5,130.75,161],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,129.14,131.51384615384615,133.8876923076923,136.26153846153846,138.6353846153846,141.00923076923075,143.3830769230769,145.75692307692307,148.13076923076923,150.5046153846154,152.87846153846152,155.25230769230768,157.62615384615384,{"y":160,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,129.14,129.7398076923077,130.33961538461537,130.93942307692308,131.53923076923076,132.13903846153846,132.73884615384614,133.33865384615385,133.93846153846152,134.53826923076923,135.1380769230769,135.73788461538462,136.3376923076923,{"y":136.9375,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,129.14,128.43692307692305,127.73384615384614,127.03076923076922,126.3276923076923,125.62461538461538,124.92153846153846,124.21846153846153,123.5153846153846,122.81230769230768,122.10923076923076,121.40615384615384,120.70307692307692,{"y":120,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.51,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.02,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.22,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.14,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.23,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.14,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$160.00Average Price Target$136.94Lowest Price Target$120.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on GH
Vijay Kumar
Evercore ISI
Evercore ISI
$95→$160
Buy
77.07%
Upside
Upgraded
06/02/26
Guardant Health upgraded to Outperform from In Line at Evercore ISIGuardant Health upgraded to Outperform from In Line at Evercore ISI
Wolfe Research Analyst forecast on GH
Unknown Analyst
Wolfe Research
Not Ranked
Wolfe Research
$120→$150
Buy
66.00%
Upside
Assigned
06/01/26
Guardant Health assumed with an Outperform at Wolfe ResearchGuardant Health assumed with an Outperform at Wolfe Research
Wells Fargo Analyst forecast on GH
Brandon Couillard
Wells Fargo
Wells Fargo
$125
Buy
38.34%
Upside
Reiterated
05/28/26
Analysts Are Bullish on Top Healthcare Stocks: Niagen Bioscience (NAGE), Guardant Health (GH)
Guggenheim Analyst forecast on GH
Subbu Nambi
Guggenheim
Guggenheim
$135
Buy
49.40%
Upside
Reiterated
05/28/26
Guggenheim Sticks to Their Buy Rating for Guardant Health (GH)
Piper Sandler Analyst forecast on GH
David Westenberg
Piper Sandler
Piper Sandler
$135
Buy
49.40%
Upside
Reiterated
05/28/26
Guardant Health (GH) Gets a Buy from Piper Sandler
Stifel Nicolaus Analyst forecast on GH
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$130
Buy
43.87%
Upside
Reiterated
05/28/26
Analysts Are Bullish on Top Healthcare Stocks: Korro Bio (KRRO), Veeva Systems (VEEV)
Canaccord Genuity Analyst forecast on GH
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$135
Buy
49.40%
Upside
Reiterated
05/28/26
Canaccord Genuity Reaffirms Their Buy Rating on Guardant Health (GH)
Barclays Analyst forecast on GH
Luke Sergott
Barclays
Barclays
$115→$120
Buy
32.80%
Upside
Reiterated
05/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
William Blair Analyst forecast on GH
Andrew Brackmann
William Blair
William Blair
―
Buy
―
Reiterated
05/27/26
Stifel Reiterates Buy on Guardant Health as ACS Guideline Inclusion of Shield Test Expands Market Opportunity
Morgan Stanley Analyst forecast on GH
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$96.71→$130
Buy
43.87%
Upside
Reiterated
05/27/26
Guardant Health: ACS Shield Endorsement and Camizestrant FDA Tailwind Prompt Price Target Increase to $130 and Reinforce Buy Rating
BTIG Analyst forecast on GH
Mark Massaro
BTIG
BTIG
$155→$160
Buy
77.07%
Upside
Reiterated
05/27/26
Guardant Health price target raised to $155 from $145 at BTIGGuardant Health price target raised to $155 from $145 at BTIG
TD Cowen Analyst forecast on GH
Daniel Brennan
TD Cowen
TD Cowen
$120→$127
Buy
40.55%
Upside
Assigned
05/08/26
Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH) and Crinetics Pharmaceuticals (NASDAQ: CRNX)
Robert W. Baird Analyst forecast on GH
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$120→$129
Buy
42.76%
Upside
Reiterated
05/08/26
Guardant Health price target raised to $129 from $120 at BairdGuardant Health price target raised to $129 from $120 at Baird
J.P. Morgan Analyst forecast on GH
Casey Woodring
J.P. Morgan
J.P. Morgan
$130→$135
Buy
49.40%
Upside
Assigned
05/08/26
Guardant Health price target raised to $135 from $130 at JPMorganGuardant Health price target raised to $135 from $130 at JPMorgan
Bank of America Securities Analyst forecast on GH
Michael Ryskin
Bank of America Securities
Bank of America Securities
$135
Buy
49.40%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH), ImageneBio (NASDAQ: IMA) and Natera (NASDAQ: NTRA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on GH
Vijay Kumar
Evercore ISI
Evercore ISI
$95→$160
Buy
77.07%
Upside
Upgraded
06/02/26
Guardant Health upgraded to Outperform from In Line at Evercore ISIGuardant Health upgraded to Outperform from In Line at Evercore ISI
Wolfe Research Analyst forecast on GH
Unknown Analyst
Wolfe Research
Not Ranked
Wolfe Research
$120→$150
Buy
66.00%
Upside
Assigned
06/01/26
Guardant Health assumed with an Outperform at Wolfe ResearchGuardant Health assumed with an Outperform at Wolfe Research
Wells Fargo Analyst forecast on GH
Brandon Couillard
Wells Fargo
Wells Fargo
$125
Buy
38.34%
Upside
Reiterated
05/28/26
Analysts Are Bullish on Top Healthcare Stocks: Niagen Bioscience (NAGE), Guardant Health (GH)
Guggenheim Analyst forecast on GH
Subbu Nambi
Guggenheim
Guggenheim
$135
Buy
49.40%
Upside
Reiterated
05/28/26
Guggenheim Sticks to Their Buy Rating for Guardant Health (GH)
Piper Sandler Analyst forecast on GH
David Westenberg
Piper Sandler
Piper Sandler
$135
Buy
49.40%
Upside
Reiterated
05/28/26
Guardant Health (GH) Gets a Buy from Piper Sandler
Stifel Nicolaus Analyst forecast on GH
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$130
Buy
43.87%
Upside
Reiterated
05/28/26
Analysts Are Bullish on Top Healthcare Stocks: Korro Bio (KRRO), Veeva Systems (VEEV)
Canaccord Genuity Analyst forecast on GH
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$135
Buy
49.40%
Upside
Reiterated
05/28/26
Canaccord Genuity Reaffirms Their Buy Rating on Guardant Health (GH)
Barclays Analyst forecast on GH
Luke Sergott
Barclays
Barclays
$115→$120
Buy
32.80%
Upside
Reiterated
05/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
William Blair Analyst forecast on GH
Andrew Brackmann
William Blair
William Blair
―
Buy
―
Reiterated
05/27/26
Stifel Reiterates Buy on Guardant Health as ACS Guideline Inclusion of Shield Test Expands Market Opportunity
Morgan Stanley Analyst forecast on GH
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$96.71→$130
Buy
43.87%
Upside
Reiterated
05/27/26
Guardant Health: ACS Shield Endorsement and Camizestrant FDA Tailwind Prompt Price Target Increase to $130 and Reinforce Buy Rating
BTIG Analyst forecast on GH
Mark Massaro
BTIG
BTIG
$155→$160
Buy
77.07%
Upside
Reiterated
05/27/26
Guardant Health price target raised to $155 from $145 at BTIGGuardant Health price target raised to $155 from $145 at BTIG
TD Cowen Analyst forecast on GH
Daniel Brennan
TD Cowen
TD Cowen
$120→$127
Buy
40.55%
Upside
Assigned
05/08/26
Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH) and Crinetics Pharmaceuticals (NASDAQ: CRNX)
Robert W. Baird Analyst forecast on GH
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$120→$129
Buy
42.76%
Upside
Reiterated
05/08/26
Guardant Health price target raised to $129 from $120 at BairdGuardant Health price target raised to $129 from $120 at Baird
J.P. Morgan Analyst forecast on GH
Casey Woodring
J.P. Morgan
J.P. Morgan
$130→$135
Buy
49.40%
Upside
Assigned
05/08/26
Guardant Health price target raised to $135 from $130 at JPMorganGuardant Health price target raised to $135 from $130 at JPMorgan
Bank of America Securities Analyst forecast on GH
Michael Ryskin
Bank of America Securities
Bank of America Securities
$135
Buy
49.40%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH), ImageneBio (NASDAQ: IMA) and Natera (NASDAQ: NTRA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Guardant Health

3 Months
David WestenbergPiper Sandler
Success Rate
15/23 ratings generated profit
65%
Average Return
+20.10%
Copying David Westenberg's trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +20.10% per trade.
1 Year
Daniel BrennanTD Cowen
Success Rate
16/17 ratings generated profit
94%
Average Return
+93.60%
Copying Daniel Brennan's trades and holding each position for 1 Year would result in 94.12% of your transactions generating a profit, with an average return of +93.60% per trade.
2 Years
Daniel BrennanTD Cowen
Success Rate
17/17 ratings generated profit
100%
Average Return
+195.82%
Copying Daniel Brennan's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +195.82% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GH Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
3
2
7
7
7
Buy
42
33
26
32
32
Hold
2
2
2
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
47
37
35
41
41
In the current month, GH has received 39 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. GH average Analyst price target in the past 3 months is 136.94.
Each month's total comprises the sum of three months' worth of ratings.

GH Financial Forecast

GH Earnings Forecast

Next quarter’s earnings estimate for GH is -$0.76 with a range of -$0.84 to -$0.60. The previous quarter’s EPS was -$0.85. GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.
Next quarter’s earnings estimate for GH is -$0.76 with a range of -$0.84 to -$0.60. The previous quarter’s EPS was -$0.85. GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.

GH Sales Forecast

Next quarter’s sales forecast for GH is $313.39M with a range of $300.80M to $322.10M. The previous quarter’s sales results were $301.67M. GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.
Next quarter’s sales forecast for GH is $313.39M with a range of $300.80M to $322.10M. The previous quarter’s sales results were $301.67M. GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.

GH Stock Forecast FAQ

What is GH’s average 12-month price target, according to analysts?
Based on analyst ratings, Guardant Health’s 12-month average price target is 136.94.
    What is GH’s upside potential, based on the analysts’ average price target?
    Guardant Health has 51.55% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GH a Buy, Sell or Hold?
          Guardant Health has a consensus rating of Strong Buy which is based on 17 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Guardant Health’s price target?
            The average price target for Guardant Health is 136.94. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $160.00 ,the lowest forecast is $120.00. The average price target represents 51.55% Increase from the current price of $90.36.
              What do analysts say about Guardant Health?
              Guardant Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of GH?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.